June 3, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15, in Stockholm on June 10 at 14.40 CET. The presentation will be livestreamed and can be followed at www.redeye.se/live/redeye-growth-day-19.
The presentation will also be available afterwards at www.redeye.se/live/redeye-growth-day-19, on the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals), as well as on the company’s website (www.indexpharma.com).
For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: [email protected]
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Stockholm. Redeye AB with email address [email protected] and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.
The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on June 3, 2019.